Pa­tients and in­ter­ested pub­lic

Risks and Be­ne­fits

Cur­rent treat­ment of AMD can be un­sat­is­fy­ing, due to fre­quency of in­jec­tions, which ne­ces­sit­ates reg­u­lar vis­its to the clin­ic. The Tar­get­AMD treat­ment aims at only one 1‑hour sur­gic­al ses­sion to deli­ver a safe and life-long solu­tion that re­sults in a com­fort­able and cost-ef­fi­cient cur­at­ive treat­ment.

TargetAMD riks and benefits

Our ap­proach of­fers:

  • Lowered costs: Only one dose of cur­rent AMD drugs used costs about 1,000 € ex­clus­ive the cost for the med­ic­al act per­formed by the oph­thal­mo­lo­gist. If one con­siders that about 8 in­jec­tions per year are needed, the cur­rent yearly drug costs are about 8,000 € per year for the life of the pa­tients plus costs for every in­jec­tion it­self. Our treat­ment just re­quires one drug dose which will cost about 3,500 € plus costs for one in­jec­tion.
  • Safe: The Sleep­ing Beauty trans­po­son sys­tem used to mul­tiply thera­peut­ic genes, has been shown as an ef­fi­cient, stable, and safe meth­od.
    As in any sur­gic­al pro­ced­ure, ad­verse ef­fects, al­though rare, can oc­cur. Po­ten­tial ad­verse ef­fects par­tic­u­lar for our ap­proach can hap­pen dur­ing the punc­ture of the iris to har­vest cells, which can cause blood ac­cu­mu­la­tion and lead to el­ev­a­tion of in­traocu­lar pres­sure that can be treated phar­ma­ceut­ic­ally, or in severe cases, sur­gic­ally. Oth­er ex­ceed­ingly rare ad­verse ef­fects could be glare, dip­lopia or mis­pos­i­tion­ing of an ex­ist­ing in­traocu­lar lens or sim­il­ar im­plant.
  • Im­prove­ment of qual­ity of life: A unique life-long-act­ing in­jec­tion of our product will pre­vent pa­tients from ha­ving re­peated dis­tress­ing vis­its to the clin­ic; thus, ease com­pli­ance to the treat­ment. Pre­served, and hope­fully im­proved vis­ion will posi­tively af­fect psy­cho­lo­gic­al health and func­tion­al status of pa­tients, keep­ing them mo­bile, in­de­pend­ent and act­ive.